Precision Therapy for Cancer Patients
Press releases
EVENTS, PRESENTATIONS & INTERVIEWS
Watch presentation by CEO Steve Carchedi
“Investerarafton” was recorded on 5 November 2019 in Stockholm, Sweden.
Company Snapshot
Oncology Venture
We are building a personalized medicine company developing new therapeutics for unmet needs in the treatment of human cancers through use of our world-class predictive diagnostics platform.
Founded in 2004 in Denmark and publicly traded on NASDAQ First North (Stockholm).
Robust pipeline of 7 novel anti-cancer drugs
Robust Pipeline of 7 novel anti-cancer drugs that address significant cancer markets.
3 prioritized clinical programs
- Dovitinib
- 2X-121
- Ixempra®
Best-in-class DRP® platform
Best-in-class DRP® platform creates drug-specific, predictive diagnostics to:
- Help select & treat the most likely responder patients for each of our pipeline drugs.
- Accelerate clinical development of each of our programs.
Strong intellectual property position
Strong intellectual property position with over 30 patents/applications in key world markets, covering DRP® diagnostics for more than 75 different cancer drugs.
Analyst Coverage
Oncology Venture is covered by a number of publications. Here you find links to their most recent updates regarding the company.
Edison Investment Research
Økonomisk Ugebrev
BioStock
science
The DRP® Method
By combining cutting-edge science from the fields of genetics and oncology, Oncology Venture is the first to develop a Drug Response Predictor®, which can be combined with ultimately any cancer drug. Using this technology, our offset is treating the particular genetic characteristics of the tumor instead of the type of cancer, which has been the traditional treatment approach. Because cancers are different. Just like people.
